Phase 3 data show tildrakizumab’s (Ilumya, Sun Pharma) efficacy and safety last up to five years.
According to a recent meta-analysis, patients who stop and restart biologic treatment can regain psoriasis control without experiencing unexpected safety issues.
Using a novel autoantigen array, researchers have shown that the IgG4 anti-gliadin autoantibody might provide useful information for diagnosis and prognosis of psoriasis.
Twice-weekly treatment with calcipotriene-betamethasone diproprionate provides safe and effective maintenance treatment for plaque psoriasis, according to phase 3 data.
Studies offer further insight into risks associated with biologic therapy. One study suggests it’s not necessary to stop biologic therapy preoperatively to limit post-operative infections. Another systematic review does not rule out melanoma risk.
Phase 3 data announced at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020 demonstrate that the second-generation IL-17 inhibitor may offer long-lasting, safe treatment for patients with psoriasis.
With newer biologics consistently posting PASI improvements greater than 90%, dermatologists need to consider other factors when selecting a treatment. However, nuanced differences between the same drug class could be teased out, one expert says.
A recent study shows ixekizumab may be able to help treat moderate-to-severe cases of genital psoriasis.
A recent article shows oral apremilast may rapidly and significantly improve moderate-to-severe scalp psoriasis.